Companies: 10,795·Total market cap: $144.5T
Design Therapeutics, Inc.

Design Therapeutics, Inc.

DSGNNASDAQHealthcare● Active
$10.50
$-0.15(-1.42%)
Market Cap$655717033
P/E Ratio
52W High$17.25
52W Low$3.33
Overview

Design Therapeutics, Inc. (DSGN) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · DSGN · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-1.20dsgn eps ttm · dsgn earnings per shareEarnings history
PE Ratio (TTM)dsgn pe ratio ttm · dsgn price to earningsPE Ratio deep dive
Revenue (TTM)0.00dsgn revenue ttm · dsgn annual revenueFull revenue history
Dividend YieldNo Dividenddoes dsgn pay dividends · dsgn dividend yieldDividend history
Shares Outstanding57.3Mdsgn shares outstanding · dsgn floatShares outstanding history
Next EarningsAug 6, 2026Est.dsgn earnings date · dsgn next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
design therapeutics, inc. revenue · dsgn revenue 2025
FY 2025Net Income-$69.8M▼ 40.74% YoY
202320242025
design therapeutics, inc. net income · dsgn profit 2025
FY 2025EPS$-1.22▼ 38.64% YoY
202320242025
dsgn eps · design therapeutics, inc. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$69.7MEPS: $-1.20View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy7 analystsis dsgn a buy · dsgn analyst rating
Strong Buy
0
Buy
4
Hold
3
Sell
0
Strong Sell
0
12-Month Price Target
$20.00Low
$10.50Current
$20.50Avg Target95.26% upside
$21.00High
dsgn price target · dsgn 12 month forecast

Total: 7 · Buy rate: 57.1%

The DSGN analyst consensus is Buy, based on ratings from 7 Wall Street analysts over the past 3 months. The average 12-month price target is $20.50, representing +95.26% upside from the current price of $10.50.

Stock Performance

Full History
1D+2.07%
1W+7.09%
1M-23.56%
3M+8.16%
YTD+15.88%
1Y+178.01%
5Y-60.63%

About Design Therapeutics, Inc.

CEOPratik Shah
IPO DateMar 29, 2021
Employees56
CountryUS

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The compa…

what is design therapeutics, inc. · dsgn stock overview · design therapeutics, inc. company profile · who is design therapeutics, inc. ceo · dsgn NASDAQ · design therapeutics, inc. headquarters · design therapeutics, inc. business segments

About Stock Overview & Key Data

Design Therapeutics, Inc. (DSGN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Mar 29, 2021. As of the latest trading session, DSGN stock price is $10.50, with a market capitalization of $655.7M. The stock has returned +178.01% over the past 12 months and +15.88% year-to-date.

According to 7 Wall Street analysts, the consensus rating for Design Therapeutics, Inc. stock is Buy, with an average 12-month price target of $20.50. In fiscal year 2025, Design Therapeutics, Inc. reported revenue of — and net income of -$69.8M. For detailed data — including Design Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Design Therapeutics, Inc. (DSGN) stock price is $10.50. The stock is traded on NASDAQ under the ticker symbol DSGN. The 52-week range is $3.33 – $17.25.

DSGN stock priceDSGN quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice